{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:43:03Z","timestamp":1792694583035,"version":"4.5.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100015360","name":"State Key Laboratory of Infectious Disease Prevention and Control","doi-asserted-by":"publisher","award":["2022SKLID306"],"award-info":[{"award-number":["2022SKLID306"]}],"id":[{"id":"10.13039\/501100015360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T2488101"],"award-info":[{"award-number":["T2488101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071417"],"award-info":[{"award-number":["82071417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00415-025-13590-3","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T18:19:51Z","timestamp":1766686791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiple system atrophy: advances in pathogenesis and emerging therapeutic strategies"],"prefix":"10.1007","volume":"273","author":[{"given":"Zhiqing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6051-2241","authenticated-orcid":false,"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"13590_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372:249\u2013263","journal-title":"N Engl J Med"},{"key":"13590_CR2","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1474-4422(24)00396-X","volume":"23","author":"F Krismer","year":"2024","unstructured":"Krismer F, Fanciulli A, Meissner WG, Coon EA, Wenning GK (2024) Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment. Lancet Neurol 23:1252\u20131266","journal-title":"Lancet Neurol"},{"key":"13590_CR3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neurol.2023.11.013","volume":"180","author":"S Kaplan","year":"2024","unstructured":"Kaplan S (2024) Prevalence of multiple system atrophy: A literature review. Rev Neurol (Paris) 180:438\u2013450","journal-title":"Rev Neurol (Paris)"},{"key":"13590_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2019.05.040","volume":"65","author":"Y Compta","year":"2019","unstructured":"Compta Y et al (2019) Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. Parkinsonism Relat Disord 65:3\u201312","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0404.2007.00991.x","volume":"118","author":"L Wermuth","year":"2008","unstructured":"Wermuth L et al (2008) Prevalence and incidence of Parkinson\u2019s disease in The Faroe Islands. Acta Neurol Scand 118:126\u2013131","journal-title":"Acta Neurol Scand"},{"key":"13590_CR6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000195686","volume":"32","author":"A Shibata-Hamaguchi","year":"2009","unstructured":"Shibata-Hamaguchi A, Ishida C, Iwasa K, Yamada M (2009) Prevalence of spinocerebellar degenerations in the Hokuriku district in Japan. Neuroepidemiology 32:176\u2013183","journal-title":"Neuroepidemiology"},{"key":"13590_CR7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1600-0404.2010.01442.x","volume":"124","author":"Y Osaki","year":"2011","unstructured":"Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y (2011) Prevalence of Parkinson\u2019s disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 124:182\u2013187","journal-title":"Acta Neurol Scand"},{"key":"13590_CR8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning GK et al (2022) The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord 37:1131\u20131148","journal-title":"Mov Disord"},{"key":"13590_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2183\/pjab.93.016","volume":"93","author":"T Ozawa","year":"2017","unstructured":"Ozawa T, Onodera O (2017) Multiple system atrophy: clinicopathological characteristics in Japanese patients. Proc Jpn Acad Ser B Phys Biol Sci 93:251\u2013258","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"13590_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s40478-025-02107-8","volume":"13","author":"JH Shin","year":"2025","unstructured":"Shin JH et al (2025) Distinct spatial transcriptomic patterns of substantia Nigra in Parkinson disease and Parkinsonian subtype of multiple system atrophy. Acta Neuropathol Commun 13:193","journal-title":"Acta Neuropathol Commun"},{"key":"13590_CR11","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/ana.70029","volume":"98","author":"Y Zheng","year":"2025","unstructured":"Zheng Y et al (2025) \u03b1-Synuclein Promotes the Expression and Release of Neurofilament Light Chain from Oligodendrocytes in a Murine Model: Implication for Multiple System Atrophy? Ann Neurol 98:1364\u20131379","journal-title":"Ann Neurol"},{"key":"13590_CR12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-019-0730-6","volume":"7","author":"G Monzio Compagnoni","year":"2019","unstructured":"Monzio Compagnoni G, Di Fonzo A (2019) Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathol Commun 7:113","journal-title":"Acta Neuropathol Commun"},{"key":"13590_CR13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-022-00382-6","volume":"8","author":"W Poewe","year":"2022","unstructured":"Poewe W et al (2022) Multiple system atrophy. Nat Rev Dis Primers 8:56","journal-title":"Nat Rev Dis Primers"},{"key":"13590_CR14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12967-023-03905-1","volume":"21","author":"FS Tseng","year":"2023","unstructured":"Tseng FS, Foo JQX, Mai AS, Tan EK (2023) The genetic basis of multiple system atrophy. J Transl Med 21:104","journal-title":"J Transl Med"},{"key":"13590_CR15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00401-022-02476-7","volume":"144","author":"SAM Holec","year":"2022","unstructured":"Holec SAM et al (2022) Multiple system atrophy prions transmit neurological disease to mice expressing wild-type human \u03b1-synuclein. Acta Neuropathol 144:677\u2013690","journal-title":"Acta Neuropathol"},{"key":"13590_CR16","volume":"33","author":"S Zhang","year":"2023","unstructured":"Zhang S et al (2023) Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson\u2019s disease patient brain spread after intracerebral injection into mouse brain. Brain Pathol 33:e13196","journal-title":"Brain Pathol"},{"key":"13590_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11910-024-01335-0","volume":"24","author":"D Bendetowicz","year":"2024","unstructured":"Bendetowicz D et al (2024) Recent Advances in Clinical Trials in Multiple System Atrophy. Curr Neurol Neurosci Rep 24:95\u2013112","journal-title":"Curr Neurol Neurosci Rep"},{"key":"13590_CR18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archneur.64.4.545","volume":"64","author":"K Hara","year":"2007","unstructured":"Hara K et al (2007) Multiplex families with multiple system atrophy. Arch Neurol 64:545\u2013551","journal-title":"Arch Neurol"},{"key":"13590_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12311-022-01426-z","volume":"23","author":"T Matsukawa","year":"2024","unstructured":"Matsukawa T et al (2024) Clinical and Genetic Features of Multiplex Families with Multiple System Atrophy and Parkinson\u2019s Disease. Cerebellum 23:22\u201330","journal-title":"Cerebellum"},{"key":"13590_CR20","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.neuron.2024.04.002","volume":"112","author":"R Chia","year":"2024","unstructured":"Chia R et al (2024) Genome sequence analyses identify novel risk loci for multiple system atrophy. Neuron 112:2142-2156.e2145","journal-title":"Neuron"},{"key":"13590_CR21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1212\/WNL.0000000000003221","volume":"87","author":"A Sailer","year":"2016","unstructured":"Sailer A et al (2016) A genome-wide association study in multiple system atrophy. Neurology 87:1591\u20131598","journal-title":"Neurology"},{"key":"13590_CR22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007114","volume":"4","author":"A Al-Chalabi","year":"2009","unstructured":"Al-Chalabi A et al (2009) Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 4:e7114","journal-title":"PLoS ONE"},{"key":"13590_CR23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ana.21685","volume":"65","author":"SW Scholz","year":"2009","unstructured":"Scholz SW et al (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65:610\u2013614","journal-title":"Ann Neurol"},{"key":"13590_CR24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","volume":"68","author":"J Fuchs","year":"2007","unstructured":"Fuchs J et al (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68:916\u2013922","journal-title":"Neurology"},{"key":"13590_CR25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s40478-019-0873-5","volume":"7","author":"D Perez-Rodriguez","year":"2019","unstructured":"Perez-Rodriguez D et al (2019) Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. Acta Neuropathol Commun 7:219","journal-title":"Acta Neuropathol Commun"},{"key":"13590_CR26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s42255-023-00956-y","volume":"6","author":"JC Herrero Mart\u00edn","year":"2024","unstructured":"Herrero Mart\u00edn JC et al (2024) An ETFDH-driven metabolon supports OXPHOS efficiency in skeletal muscle by regulating coenzyme Q homeostasis. Nat Metab 6:209\u2013225","journal-title":"Nat Metab"},{"key":"13590_CR27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1212115","volume":"369","author":"Multiple-System Atrophy Research Collaboration","year":"2013","unstructured":"Multiple-System Atrophy Research Collaboration (2013) Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 369:233\u2013244","journal-title":"N Engl J Med"},{"key":"13590_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117623","volume":"429","author":"KJ Porto","year":"2021","unstructured":"Porto KJ et al (2021) COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population. J Neurol Sci 429:117623","journal-title":"J Neurol Sci"},{"key":"13590_CR29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cns.12412","volume":"21","author":"XD Wen","year":"2015","unstructured":"Wen XD et al (2015) Mutation Analysis of COQ2 in Chinese Patients with Cerebellar Subtype of Multiple System Atrophy. CNS Neurosci Ther 21:626\u2013630","journal-title":"CNS Neurosci Ther"},{"key":"13590_CR30","volume":"2","author":"Z Sun","year":"2016","unstructured":"Sun Z et al (2016) New susceptible variant of COQ2 gene in Japanese patients with sporadic multiple system atrophy. Neurol Genet 2:e54","journal-title":"Neurol Genet"},{"key":"13590_CR31","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3390\/ijms24032044","volume":"24","author":"Z Granek","year":"2023","unstructured":"Granek Z et al (2023) GBA1 Gene Mutations in \u03b1-Synucleinopathies-Molecular Mechanisms Underlying Pathology and Their Clinical Significance. Int J Mol Sci 24:2044","journal-title":"Int J Mol Sci"},{"key":"13590_CR32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/biom11091333","volume":"11","author":"M Teixeira","year":"2021","unstructured":"Teixeira M, Sheta R, Idi W, Oueslati A (2021) Alpha-Synuclein and the Endolysosomal System in Parkinson\u2019s Disease: Guilty by Association. Biomolecules 11:1333","journal-title":"Biomolecules"},{"key":"13590_CR33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mdc3.12481","volume":"4","author":"M Sklerov","year":"2017","unstructured":"Sklerov M et al (2017) Frequency of GBA variants in autopsy-proven multiple system atrophy. Mov Disord Clin Pract 4:574\u2013581","journal-title":"Mov Disord Clin Pract"},{"key":"13590_CR34","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.wnl.0000345356.40399.eb","volume":"72","author":"B Segarane","year":"2009","unstructured":"Segarane B et al (2009) Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 72:1185\u20131186","journal-title":"Neurology"},{"key":"13590_CR35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.parkreldis.2020.06.007","volume":"77","author":"AI Wernick","year":"2020","unstructured":"Wernick AI et al (2020) GBA variation and susceptibility to multiple system atrophy. Parkinsonism Relat Disord 77:64\u201369","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR36","volume":"9","author":"L Zhou","year":"2020","unstructured":"Zhou L et al (2020) Gab1 mediates PDGF signaling and is essential to oligodendrocyte differentiation and CNS myelination. Elife 9:e52056","journal-title":"Elife"},{"key":"13590_CR37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2353\/ajpath.2007.070201","volume":"171","author":"YJ Song","year":"2007","unstructured":"Song YJ et al (2007) p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171:1291\u20131303","journal-title":"Am J Pathol"},{"key":"13590_CR38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00401-025-02951-x","volume":"150","author":"SA Buck","year":"2025","unstructured":"Buck SA et al (2025) LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopathies and synucleinopathies. Acta Neuropathol 150:44","journal-title":"Acta Neuropathol"},{"key":"13590_CR39","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00660-20","volume":"41","author":"A Usmani","year":"2021","unstructured":"Usmani A, Shavarebi F, Hiniker A (2021) The Cell Biology of LRRK2 in Parkinson\u2019s Disease. Mol Cell Biol 41:e00660","journal-title":"Mol Cell Biol"},{"key":"13590_CR40","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.27710","volume":"34","author":"GM Riboldi","year":"2019","unstructured":"Riboldi GM et al (2019) Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation. Mov Disord 34:1080\u20131082","journal-title":"Mov Disord"},{"key":"13590_CR41","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1212\/WNL.0000000000001078","volume":"83","author":"MG Heckman","year":"2014","unstructured":"Heckman MG et al (2014) LRRK2 exonic variants and risk of multiple system atrophy. Neurology 83:2256\u20132261","journal-title":"Neurology"},{"key":"13590_CR42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-024-00731-x","volume":"19","author":"C Pedicone","year":"2024","unstructured":"Pedicone C, Weitzman SA, Renton AE, Goate AM (2024) Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases. Mol Neurodegener 19:43","journal-title":"Mol Neurodegener"},{"key":"13590_CR43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/WNL.0b013e31820c30c1","volume":"76","author":"C Vilari\u00f1o-G\u00fcell","year":"2011","unstructured":"Vilari\u00f1o-G\u00fcell C et al (2011) MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 76:670\u2013672","journal-title":"Neurology"},{"key":"13590_CR44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.parkreldis.2016.06.010","volume":"30","author":"C Labb\u00e9","year":"2016","unstructured":"Labb\u00e9 C et al (2016) MAPT haplotype diversity in multiple system atrophy. Parkinsonism Relat Disord 30:40\u201345","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/brain\/aws357","volume":"136","author":"S Lesage","year":"2013","unstructured":"Lesage S et al (2013) C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 136:385\u2013391","journal-title":"Brain"},{"key":"13590_CR46","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jamaneurol.2013.5762","volume":"71","author":"JS Goldman","year":"2014","unstructured":"Goldman JS et al (2014) Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol 71:771\u2013774","journal-title":"JAMA Neurol"},{"key":"13590_CR47","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1007\/s00415-015-7873-6","volume":"262","author":"A Cannas","year":"2015","unstructured":"Cannas A et al (2015) C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson\u2019s disease complicated by psychosis or dementia in a Sardinian population. J Neurol 262:2498\u20132503","journal-title":"J Neurol"},{"key":"13590_CR48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neurobiolaging.2021.12.003","volume":"112","author":"G Bonapace","year":"2022","unstructured":"Bonapace G et al (2022) Multiple system atrophy and C9orf72 hexanucleotide repeat expansions in a cohort of Italian patients. Neurobiol Aging 112:12\u201315","journal-title":"Neurobiol Aging"},{"key":"13590_CR49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ana.25902","volume":"88","author":"L Wan","year":"2020","unstructured":"Wan L et al (2020) Biallelic Intronic AAGGG Expansion of RFC1 is Related to Multiple System Atrophy. Ann Neurol 88:1132\u20131143","journal-title":"Ann Neurol"},{"key":"13590_CR50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acn3.51021","volume":"7","author":"P Fang","year":"2020","unstructured":"Fang P et al (2020) Repeat expansion scanning of the NOTCH2NLC gene in patients with multiple system atrophy. Ann Clin Transl Neurol 7:517\u2013526","journal-title":"Ann Clin Transl Neurol"},{"key":"13590_CR51","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000257","volume":"4","author":"K Ogaki","year":"2018","unstructured":"Ogaki K et al (2018) Association study between multiple system atrophy and TREM2 p.R47H. Neurol Genet 4:e257","journal-title":"Neurol Genet"},{"key":"13590_CR52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fnagi.2018.00150","volume":"10","author":"B Cao","year":"2018","unstructured":"Cao B et al (2018) Functional Variant rs3135500 in NOD2 Increases the Risk of Multiple System Atrophy in a Chinese Population. Front Aging Neurosci 10:150","journal-title":"Front Aging Neurosci"},{"key":"13590_CR53","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3389\/fnins.2020.00889","volume":"14","author":"Y Chen","year":"2020","unstructured":"Chen Y et al (2020) Contribution of five functional loci of dopamine metabolism-related genes to parkinson\u2019s disease and multiple system atrophy in a chinese population. Front Neurosci 14:889","journal-title":"Front Neurosci"},{"key":"13590_CR54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2990.2007.00907.x","volume":"33","author":"JQ Trojanowski","year":"2007","unstructured":"Trojanowski JQ, Revesz T (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33:615\u2013620","journal-title":"Neuropathol Appl Neurobiol"},{"key":"13590_CR55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s004010051177","volume":"99","author":"K Gwinn-Hardy","year":"2000","unstructured":"Gwinn-Hardy K et al (2000) Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 99:663\u2013672","journal-title":"Acta Neuropathol"},{"key":"13590_CR56","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00702-005-0378-1","volume":"112","author":"DW Miller","year":"2005","unstructured":"Miller DW et al (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) 112:1613\u20131624","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"13590_CR57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-pathmechdis-051122-104528","volume":"20","author":"A Ndayisaba","year":"2024","unstructured":"Ndayisaba A, Halliday GM, Khurana V (2024) Multiple System Atrophy: Pathology, Pathogenesis, and Path Forward. Annu Rev Pathol 20(1):245\u2013273","journal-title":"Annu Rev Pathol"},{"key":"13590_CR58","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/mds.26220","volume":"30","author":"H Ling","year":"2015","unstructured":"Ling H et al (2015) Minimal change multiple system atrophy: an aggressive variant? Mov Disord 30:960\u2013967","journal-title":"Mov Disord"},{"key":"13590_CR59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00401-021-02316-0","volume":"142","author":"N Ferreira","year":"2021","unstructured":"Ferreira N et al (2021) Multiple system atrophy-associated oligodendroglial protein p25\u03b1 stimulates formation of novel \u03b1-synuclein strain with enhanced neurodegenerative potential. Acta Neuropathol 142:87\u2013115","journal-title":"Acta Neuropathol"},{"key":"13590_CR60","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1080\/15548627.2021.2016256","volume":"18","author":"P Mavroeidi","year":"2022","unstructured":"Mavroeidi P et al (2022) Autophagy mediates the clearance of oligodendroglial SNCA\/alpha-synuclein and TPPP\/p25A in multiple system atrophy models. Autophagy 18:2104\u20132133","journal-title":"Autophagy"},{"key":"13590_CR61","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40478-014-0150-6","volume":"2","author":"AS Don","year":"2014","unstructured":"Don AS et al (2014) Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathol Commun 2:150","journal-title":"Acta Neuropathol Commun"},{"key":"13590_CR62","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/brain\/awac124","volume":"146","author":"V Donadio","year":"2023","unstructured":"Donadio V et al (2023) Phosphorylated \u03b1-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. Brain 146:1065\u20131074","journal-title":"Brain"},{"key":"13590_CR63","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41583-023-00697-7","volume":"24","author":"N Stefanova","year":"2023","unstructured":"Stefanova N, Wenning GK (2023) Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms. Nat Rev Neurosci 24:334\u2013346","journal-title":"Nat Rev Neurosci"},{"key":"13590_CR64","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/brain\/awab374","volume":"145","author":"M Teil","year":"2022","unstructured":"Teil M et al (2022) Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain 145:1001\u20131017","journal-title":"Brain"},{"key":"13590_CR65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/brain\/awac061","volume":"146","author":"T Torre-Muruzabal","year":"2023","unstructured":"Torre-Muruzabal T et al (2023) Host oligodendrogliopathy and \u03b1-synuclein strains dictate disease severity in multiple system atrophy. Brain 146:237\u2013251","journal-title":"Brain"},{"key":"13590_CR66","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"A Van der Perren","year":"2020","unstructured":"Van der Perren A et al (2020) The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol 139:977\u20131000","journal-title":"Acta Neuropathol"},{"key":"13590_CR67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00401-019-01961-w","volume":"137","author":"H Sekiya","year":"2019","unstructured":"Sekiya H et al (2019) Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol 137:455\u2013466","journal-title":"Acta Neuropathol"},{"key":"13590_CR68","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40478-021-01173-y","volume":"9","author":"EW Hass","year":"2021","unstructured":"Hass EW et al (2021) Robust \u03b1-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy. Acta Neuropathol Commun 9:80","journal-title":"Acta Neuropathol Commun"},{"key":"13590_CR69","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cell.2017.10.047","volume":"171","author":"DF Jarosz","year":"2017","unstructured":"Jarosz DF, Khurana V (2017) Specification of physiologic and disease states by distinct proteins and protein conformations. Cell 171:1001\u20131014","journal-title":"Cell"},{"key":"13590_CR70","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/glia.22611","volume":"62","author":"JF Reyes","year":"2014","unstructured":"Reyes JF et al (2014) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62:387\u2013398","journal-title":"Glia"},{"key":"13590_CR71","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.stemcr.2017.12.001","volume":"10","author":"S Kaji","year":"2018","unstructured":"Kaji S et al (2018) Pathological endogenous \u03b1-Synuclein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system atrophy. Stem Cell Reports 10:356\u2013365","journal-title":"Stem Cell Reports"},{"key":"13590_CR72","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/neup.12037","volume":"33","author":"T Kon","year":"2013","unstructured":"Kon T, Mori F, Tanji K, Miki Y, Wakabayashi K (2013) An autopsy case of preclinical multiple system atrophy (MSA-C). Neuropathology 33:667\u2013672","journal-title":"Neuropathology"},{"key":"13590_CR73","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0002-9440(10)62307-3","volume":"166","author":"N Stefanova","year":"2005","unstructured":"Stefanova N et al (2005) Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166:869\u2013876","journal-title":"Am J Pathol"},{"key":"13590_CR74","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.3390\/ijms232315182","volume":"23","author":"B Andrade","year":"2022","unstructured":"Andrade B et al (2022) The Relationship between Reactive Oxygen Species and the cGAS\/STING Signaling Pathway in the Inflammaging Process. Int J Mol Sci 23:15182","journal-title":"Int J Mol Sci"},{"key":"13590_CR75","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135972","volume":"757","author":"Y Inoue","year":"2021","unstructured":"Inoue Y et al (2021) The stimulator of interferon genes (STING) pathway is upregulated in striatal astrocytes of patients with multiple system atrophy. Neurosci Lett 757:135972","journal-title":"Neurosci Lett"},{"key":"13590_CR76","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00401-023-02562-4","volume":"145","author":"W Peelaerts","year":"2023","unstructured":"Peelaerts W et al (2023) Urinary tract infections trigger synucleinopathy via the innate immune response. Acta Neuropathol 145:541\u2013559","journal-title":"Acta Neuropathol"},{"key":"13590_CR77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40478-023-01710-x","volume":"12","author":"NJ Corbin-Stein","year":"2024","unstructured":"Corbin-Stein NJ et al (2024) IFN\u03b3 drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy. Acta Neuropathol Commun 12:11","journal-title":"Acta Neuropathol Commun"},{"key":"13590_CR78","doi-asserted-by":"crossref","first-page":"38387","DOI":"10.1038\/srep38387","volume":"6","author":"M Watanabe","year":"2016","unstructured":"Watanabe M et al (2016) Th1 cells downregulate connexin 43 gap junctions in astrocytes via microglial activation. Sci Rep 6:38387","journal-title":"Sci Rep"},{"key":"13590_CR79","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.26516","volume":"93","author":"JL Hsu","year":"2023","unstructured":"Hsu JL et al (2023) Magnetic Resonance Images Implicate That Glymphatic Alterations Mediate Cognitive Dysfunction in Alzheimer Disease. Ann Neurol 93:164\u2013174","journal-title":"Ann Neurol"},{"key":"13590_CR80","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/pcn.13557","volume":"77","author":"HI Chang","year":"2023","unstructured":"Chang HI et al (2023) Gray matter reserve determines glymphatic system function in young-onset Alzheimer\u2019s disease: Evidenced by DTI-ALPS and compared with age-matched controls. Psychiatry Clin Neurosci 77:401\u2013409","journal-title":"Psychiatry Clin Neurosci"},{"key":"13590_CR81","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jon.12837","volume":"31","author":"CE Steward","year":"2021","unstructured":"Steward CE et al (2021) Assessment of the DTI-ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. J Neuroimaging 31:569\u2013578","journal-title":"J Neuroimaging"},{"key":"13590_CR82","volume":"114","author":"YJ Bae","year":"2023","unstructured":"Bae YJ et al (2023) Glymphatic function assessment in Parkinson\u2019s disease using diffusion tensor image analysis along the perivascular space. Parkinsonism Relat Disord 114:105767","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR83","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/cns.13984","volume":"29","author":"X Cai","year":"2023","unstructured":"Cai X et al (2023) Diffusion along perivascular spaces provides evidence interlinking compromised glymphatic function with aging in Parkinson\u2019s disease. CNS Neurosci Ther 29:111\u2013121","journal-title":"CNS Neurosci Ther"},{"key":"13590_CR84","volume":"123","author":"C Shi","year":"2024","unstructured":"Shi C et al (2024) Impaired glymphatic clearance in multiple system atrophy: A diffusion spectrum imaging study. Parkinsonism Relat Disord 123:106950","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR85","volume":"205","author":"YR Sun","year":"2025","unstructured":"Sun YR, Lv QK, Liu JY, Wang F, Liu CF (2025) New perspectives on the glymphatic system and the relationship between glymphatic system and neurodegenerative diseases. Neurobiol Dis 205:106791","journal-title":"Neurobiol Dis"},{"key":"13590_CR86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114574","volume":"452","author":"V Schmitt","year":"2023","unstructured":"Schmitt V et al (2023) Gut-to-brain spreading of pathology in synucleinopathies: A focus on molecular signalling mediators. Behav Brain Res 452:114574","journal-title":"Behav Brain Res"},{"key":"13590_CR87","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrgastro.2016.200","volume":"14","author":"TG Dinan","year":"2017","unstructured":"Dinan TG, Cryan JF (2017) Gut-brain axis in 2016: Brain-gut-microbiota axis - mood, metabolism and behaviour. Nat Rev Gastroenterol Hepatol 14:69\u201370","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"13590_CR88","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nbd.2018.01.008","volume":"112","author":"FP Manfredsson","year":"2018","unstructured":"Manfredsson FP et al (2018) Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis 112:106\u2013118","journal-title":"Neurobiol Dis"},{"key":"13590_CR89","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR et al (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s Disease. Cell 167:1469-1480.e1412","journal-title":"Cell"},{"key":"13590_CR90","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fnins.2019.01102","volume":"13","author":"L Wan","year":"2019","unstructured":"Wan L et al (2019) Alterations of the gut microbiota in multiple system atrophy patients. Front Neurosci 13:1102","journal-title":"Front Neurosci"},{"key":"13590_CR91","doi-asserted-by":"crossref","first-page":"1210220","DOI":"10.3389\/fneur.2023.1210220","volume":"14","author":"M Goolla","year":"2023","unstructured":"Goolla M, Cheshire WP, Ross OA, Kondru N (2023) Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers. Front Neurol 14:1210220","journal-title":"Front Neurol"},{"key":"13590_CR92","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B et al (2011) \u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230\u2013240","journal-title":"Lancet Neurol"},{"issue":"430","key":"13590_CR93","first-page":"e431","volume":"33","author":"MB Aerts","year":"2012","unstructured":"Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM (2012) CSF \u03b1-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33(430):e431-433","journal-title":"Neurobiol Aging"},{"key":"13590_CR94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WAD.0b013e31823899cc","volume":"26","author":"F Tateno","year":"2012","unstructured":"Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 26:213\u2013216","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"13590_CR95","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nbd.2011.08.003","volume":"45","author":"PG Foulds","year":"2012","unstructured":"Foulds PG et al (2012) Post mortem cerebrospinal fluid \u03b1-synuclein levels are raised in multiple system atrophy and distinguish this from the other \u03b1-synucleinopathies, Parkinson\u2019s disease and Dementia with Lewy bodies. Neurobiol Dis 45:188\u2013195","journal-title":"Neurobiol Dis"},{"key":"13590_CR96","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/brainsci11010119","volume":"11","author":"VC Constantinides","year":"2021","unstructured":"Constantinides VC et al (2021) Cerebrospinal Fluid \u03b1-Synuclein Species in Cognitive and Movements Disorders. Brain Sci 11:119","journal-title":"Brain Sci"},{"key":"13590_CR97","first-page":"121ra120","volume":"4","author":"Y Wang","year":"2012","unstructured":"Wang Y et al (2012) Phosphorylated \u03b1-synuclein in Parkinson\u2019s disease. Sci Transl Med 4:121ra120","journal-title":"Sci Transl Med"},{"key":"13590_CR98","first-page":"8740419","volume":"2020","author":"XY Li","year":"2020","unstructured":"Li XY et al (2020) Phosphorylated Alpha-Synuclein in Red Blood Cells as a Potential Diagnostic Biomarker for Multiple System Atrophy: A Pilot Study. Parkinsons Dis 2020:8740419","journal-title":"Parkinsons Dis"},{"key":"13590_CR99","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2022.111842","volume":"165","author":"R Kurapova","year":"2022","unstructured":"Kurapova R, Chouliaras L, O\u2019Brien JT (2022) The promise of amplification assays for accurate early detection of \u03b1-synucleinopathies: A review. Exp Gerontol 165:111842","journal-title":"Exp Gerontol"},{"key":"13590_CR100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M et al (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140:49\u201362","journal-title":"Acta Neuropathol"},{"key":"13590_CR101","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer A et al (2023) \u03b1-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid-A Systematic Review and Meta-Analysis. Mov Disord Clin Pract 10:737\u2013747","journal-title":"Mov Disord Clin Pract"},{"key":"13590_CR102","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M et al (2020) Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578:273\u2013277","journal-title":"Nature"},{"key":"13590_CR103","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.25824","volume":"88","author":"W Singer","year":"2020","unstructured":"Singer W et al (2020) Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. Ann Neurol 88:503\u2013512","journal-title":"Ann Neurol"},{"key":"13590_CR104","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini I et al (2022) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145:584\u2013595","journal-title":"Brain"},{"key":"13590_CR105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41531-021-00232-4","volume":"7","author":"C Quadalti","year":"2021","unstructured":"Quadalti C et al (2021) Neurofilament light chain and \u03b1-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. NPJ Parkinsons Dis 7:93","journal-title":"NPJ Parkinsons Dis"},{"key":"13590_CR106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40035-023-00370-0","volume":"12","author":"L Wan","year":"2023","unstructured":"Wan L et al (2023) Multidimensional biomarkers for multiple system atrophy: an update and future directions. Transl Neurodegener 12:38","journal-title":"Transl Neurodegener"},{"key":"13590_CR107","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons CH et al (2024) Skin Biopsy Detection of Phosphorylated \u03b1-Synuclein in Patients With Synucleinopathies. JAMA 331:1298\u20131306","journal-title":"JAMA"},{"key":"13590_CR108","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00415-024-12784-5","volume":"272","author":"M Liu","year":"2024","unstructured":"Liu M et al (2024) Serum neurofilament light chain as a diagnostic and prognostic biomarker in multiple system atrophy: a prospective cohort study. J Neurol 272:74","journal-title":"J Neurol"},{"issue":"6","key":"13590_CR109","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/ana.70029","volume":"98","author":"Y Zheng","year":"2025","unstructured":"Zheng Y et al (2025) \u03b1-Synuclein promotes the expression and release of neurofilament light chain from oligodendrocytes in a murine model: implication for multiple system atrophy? Ann Neurol 98(6):1364\u20131379","journal-title":"Ann Neurol"},{"key":"13590_CR110","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/mds.28738","volume":"36","author":"I Schulz","year":"2021","unstructured":"Schulz I et al (2021) Systematic assessment of 10 biomarker candidates focusing on \u03b1-synuclein-related disorders. Mov Disord 36:2874\u20132887","journal-title":"Mov Disord"},{"key":"13590_CR111","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/brain\/awac253","volume":"145","author":"V Chelban","year":"2022","unstructured":"Chelban V et al (2022) Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 145:4398\u20134408","journal-title":"Brain"},{"key":"13590_CR112","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O et al (2017) Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930\u2013937","journal-title":"Neurology"},{"key":"13590_CR113","first-page":"e1479","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92:e1479\u2013e1486","journal-title":"Neurology"},{"key":"13590_CR114","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/glia.24589","volume":"72","author":"H Bagheri","year":"2024","unstructured":"Bagheri H et al (2024) Myelin basic protein mRNA levels affect myelin sheath dimensions, architecture, plasticity, and density of resident glial cells. Glia 72:1893\u20131914","journal-title":"Glia"},{"key":"13590_CR115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00415-024-12747-w","volume":"272","author":"F Maass","year":"2024","unstructured":"Maass F et al (2024) Myelin basic protein and TREM2 quantification in the CSF of patients with Multiple System Atrophy and other Parkinsonian conditions. J Neurol 272:52","journal-title":"J Neurol"},{"key":"13590_CR116","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.parkreldis.2020.06.004","volume":"76","author":"A Santaella","year":"2020","unstructured":"Santaella A et al (2020) Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy. Parkinsonism Relat Disord 76:80\u201384","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"13590_CR117","doi-asserted-by":"crossref","first-page":"15576","DOI":"10.1007\/s12035-025-05219-3","volume":"62","author":"EMS Bandara","year":"2025","unstructured":"Bandara EMS et al (2025) The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer\u2019s Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression. Mol Neurobiol 62(12):15576\u201315608","journal-title":"Mol Neurobiol"},{"key":"13590_CR118","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1007\/s00415-024-12647-z","volume":"271","author":"S Katzdobler","year":"2024","unstructured":"Katzdobler S et al (2024) GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). J Neurol 271:6991\u20136999","journal-title":"J Neurol"},{"key":"13590_CR119","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41531-023-00481-5","volume":"9","author":"Y Guo","year":"2023","unstructured":"Guo Y et al (2023) Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy. NPJ Parkinsons Dis 9:40","journal-title":"NPJ Parkinsons Dis"},{"key":"13590_CR120","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.108014","volume":"140","author":"MJ Firbank","year":"2025","unstructured":"Firbank MJ et al (2025) Changes in DTI-ALPS index and its associations with neuronal damage in Lewy body disease. Parkinsonism Relat Disord 140:108014","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR121","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mds.27344","volume":"33","author":"JA Palma","year":"2018","unstructured":"Palma JA, Kaufmann H (2018) Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 33:372\u2013390","journal-title":"Mov Disord"},{"key":"13590_CR122","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12311-022-01411-6","volume":"22","author":"A Grossauer","year":"2023","unstructured":"Grossauer A, Sidoroff V, Heim B, Seppi K (2023) Symptomatic care in multiple system atrophy: state of the art. Cerebellum 22:433\u2013446","journal-title":"Cerebellum"},{"key":"13590_CR123","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3233\/JPD-223183","volume":"12","author":"V Sidoroff","year":"2022","unstructured":"Sidoroff V et al (2022) Disease-modifying therapies for multiple system atrophy: where are we in 2022? J Parkinsons Dis 12:1369\u20131387","journal-title":"J Parkinsons Dis"},{"key":"13590_CR124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19:673\u2013694","journal-title":"Nat Rev Drug Discov"},{"key":"13590_CR125","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4103\/1673-5374.340409","volume":"18","author":"BP Imbimbo","year":"2023","unstructured":"Imbimbo BP, Triaca V, Imbimbo C, Nistic\u00f2 R (2023) Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials. Neural Regen Res 18:1679\u20131683","journal-title":"Neural Regen Res"},{"key":"13590_CR126","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/nat.2018.0775","volume":"29","author":"M Imbert","year":"2019","unstructured":"Imbert M, Blandel F, Leumann C, Garcia L, Goyenvalle A (2019) Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington\u2019s Disease. Nucleic Acid Ther 29:256\u2013265","journal-title":"Nucleic Acid Ther"},{"key":"13590_CR127","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41398-022-01842-z","volume":"12","author":"L Miquel-Rio","year":"2022","unstructured":"Miquel-Rio L et al (2022) Human \u03b1-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype Rescue by oligonucleotide therapy. Transl Psychiatry 12:79","journal-title":"Transl Psychiatry"},{"key":"13590_CR128","first-page":"15576","volume":"6","author":"TA Cole","year":"2021","unstructured":"Cole TA et al (2021) \u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease. JCI Insight 6:15576\u201315608","journal-title":"JCI Insight"},{"key":"13590_CR129","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3233\/JPD-212566","volume":"11","author":"SW Boutros","year":"2021","unstructured":"Boutros SW, Raber J, Unni VK (2021) Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex. J Parkinsons Dis 11:1091\u20131115","journal-title":"J Parkinsons Dis"},{"key":"13590_CR130","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.3390\/ijms21165724","volume":"21","author":"CA Morato Torres","year":"2020","unstructured":"Morato Torres CA et al (2020) The Role of Alpha-Synuclein and Other Parkinson\u2019s Genes in Neurodevelopmental and Neurodegenerative Disorders. Int J Mol Sci 21:5724","journal-title":"Int J Mol Sci"},{"key":"13590_CR131","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105218","volume":"148","author":"J Yang","year":"2021","unstructured":"Yang J et al (2021) Exosome-mediated delivery of antisense oligonucleotides targeting \u03b1-synuclein ameliorates the pathology in a mouse model of Parkinson\u2019s disease. Neurobiol Dis 148:105218","journal-title":"Neurobiol Dis"},{"key":"13590_CR132","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jconrel.2019.11.009","volume":"317","author":"G Kim","year":"2020","unstructured":"Kim G et al (2020) Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. J Control Release 317:273\u2013281","journal-title":"J Control Release"},{"key":"13590_CR133","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1007\/s00415-024-12269-5","volume":"271","author":"M Liu","year":"2024","unstructured":"Liu M, Wang Z, Shang H (2024) Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials. J Neurol 271:2324\u20132344","journal-title":"J Neurol"},{"key":"13590_CR134","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.28218","volume":"35","author":"WG Meissner","year":"2020","unstructured":"Meissner WG et al (2020) A Phase 1 Randomized Trial of Specific Active \u03b1-Synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Mov Disord 35:1957\u20131965","journal-title":"Mov Disord"},{"key":"13590_CR135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/mds.29016","volume":"37","author":"HJ Yu","year":"2022","unstructured":"Yu HJ et al (2022) A Randomized First-in-Human Study With UB-312, a UBITh\u00ae \u03b1-Synuclein Peptide Vaccine. Mov Disord 37:1416\u20131424","journal-title":"Mov Disord"},{"key":"13590_CR136","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","volume":"132","author":"DJ Schofield","year":"2019","unstructured":"Schofield DJ et al (2019) Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo. Neurobiol Dis 132:104582","journal-title":"Neurobiol Dis"},{"key":"13590_CR137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41531-023-00484-2","volume":"9","author":"J Obergasteiger","year":"2023","unstructured":"Obergasteiger J et al (2023) The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology. NPJ Parkinsons Dis 9:44","journal-title":"NPJ Parkinsons Dis"},{"key":"13590_CR138","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1212\/WNL.0000000000202579","volume":"100","author":"C Shering","year":"2023","unstructured":"Shering C et al (2023) Reducing \u03b1-Synuclein in Human CSF; An Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1341, an \u03b1-Synuclein-specific antibody, in Healthy Volunteers and Parkinson\u2019s Disease Patients (P1\u201311.007). Neurology 100:2469","journal-title":"Neurology"},{"key":"13590_CR139","doi-asserted-by":"crossref","first-page":"1994690","DOI":"10.1080\/19420862.2021.1994690","volume":"13","author":"L Fjord-Larsen","year":"2021","unstructured":"Fjord-Larsen L et al (2021) Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs 13:1994690","journal-title":"MAbs"},{"key":"13590_CR140","doi-asserted-by":"crossref","first-page":"8453","DOI":"10.3390\/ijms22168453","volume":"22","author":"T Umeda","year":"2021","unstructured":"Umeda T, Hatanaka Y, Sakai A, Tomiyama T (2021) Nasal rifampicin improves cognition in a mouse model of dementia with lewy bodies by reducing \u03b1-Synuclein Oligomers. Int J Mol Sci 22:8453","journal-title":"Int J Mol Sci"},{"key":"13590_CR141","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1093\/hmg\/ddu391","volume":"23","author":"O Chutna","year":"2014","unstructured":"Chutna O et al (2014) The small GTPase Rab11 co-localizes with \u03b1-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Hum Mol Genet 23:6732\u20136745","journal-title":"Hum Mol Genet"},{"key":"13590_CR142","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","volume":"13","author":"PA Low","year":"2014","unstructured":"Low PA et al (2014) Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:268\u2013275","journal-title":"Lancet Neurol"},{"key":"13590_CR143","volume":"230","author":"Z Yang","year":"2023","unstructured":"Yang Z et al (2023) EGCG attenuates \u03b1-synuclein protofibril-membrane interactions and disrupts the protofibril. Int J Biol Macromol 230:123194","journal-title":"Int J Biol Macromol"},{"key":"13590_CR144","doi-asserted-by":"crossref","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","volume":"289","author":"N Lorenzen","year":"2014","unstructured":"Lorenzen N et al (2014) How epigallocatechin gallate can inhibit \u03b1-synuclein oligomer toxicity in vitro. J Biol Chem 289:21299\u201321310","journal-title":"J Biol Chem"},{"key":"13590_CR145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neuroscience.2014.12.003","volume":"286","author":"M Chen","year":"2015","unstructured":"Chen M et al (2015) Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral \u03b1-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. Neuroscience 286:383\u2013392","journal-title":"Neuroscience"},{"key":"13590_CR146","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","volume":"18","author":"J Levin","year":"2019","unstructured":"Levin J et al (2019) Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 18:724\u2013735","journal-title":"Lancet Neurol"},{"key":"13590_CR147","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/WNR.0b013e328354a1f0","volume":"23","author":"F Febbraro","year":"2012","unstructured":"Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M (2012) \u03b1-Synuclein expression is modulated at the translational level by iron. NeuroReport 23:576\u2013580","journal-title":"NeuroReport"},{"key":"13590_CR148","volume":"16","author":"DK Bailey","year":"2021","unstructured":"Bailey DK, Clark W, Kosman DJ (2021) The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells. PLoS ONE 16:e0254794","journal-title":"PLoS ONE"},{"key":"13590_CR149","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","volume":"5","author":"DI Finkelstein","year":"2017","unstructured":"Finkelstein DI et al (2017) The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease. Acta Neuropathol Commun 5:53","journal-title":"Acta Neuropathol Commun"},{"key":"13590_CR150","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1212\/WNL.94.15_supplement.4871","volume":"94","author":"DA Stamler","year":"2020","unstructured":"Stamler DA, Bradbury MJ, Wong C, Offman E (2020) A Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of \u03b1-Synuclein Aggregation, in Adult and Older Adult Volunteers. Neurology 94:4871","journal-title":"Neurology"},{"key":"13590_CR151","unstructured":"Bhushan B et al (2025) The fragile balance: autophagy's role in neurodegenerative disease progression. Curr Neuropharmacol"},{"key":"13590_CR152","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.apsb.2022.01.017","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C et al (2022) Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: Implications for Alzheimer\u2019s disease therapy. Acta Pharm Sin B 12:1707\u20131722","journal-title":"Acta Pharm Sin B"},{"key":"13590_CR153","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129719","volume":"4","author":"ML Arotcarena","year":"2019","unstructured":"Arotcarena ML et al (2019) Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. JCI Insight 4:e129719","journal-title":"JCI Insight"},{"key":"13590_CR154","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105821","volume":"115","author":"KA Pucha","year":"2023","unstructured":"Pucha KA et al (2023) Neuron-derived extracellular vesicles to examine brain mTOR target engagement with sirolimus in patients with multiple system atrophy. Parkinsonism Relat Disord 115:105821","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR155","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mds.28923","volume":"37","author":"JA Palma","year":"2022","unstructured":"Palma JA et al (2022) mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis. Mov Disord 37:778\u2013789","journal-title":"Mov Disord"},{"key":"13590_CR156","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12868-015-0222-y","volume":"16","author":"L Hou","year":"2015","unstructured":"Hou L et al (2015) Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement. BMC Neurosci 16:82","journal-title":"BMC Neurosci"},{"key":"13590_CR157","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00415-012-6655-7","volume":"260","author":"F Sacc\u00e0","year":"2013","unstructured":"Sacc\u00e0 F et al (2013) A randomized clinical trial of lithium in multiple system atrophy. J Neurol 260:458\u2013461","journal-title":"J Neurol"},{"key":"13590_CR158","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.chembiol.2020.03.010","volume":"27","author":"J Qu","year":"2020","unstructured":"Qu J et al (2020) Specific Knockdown of \u03b1-Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity. Cell Chem Biol 27:751-762.e754","journal-title":"Cell Chem Biol"},{"key":"13590_CR159","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jnen\/63.1.43","volume":"63","author":"K Ishizawa","year":"2004","unstructured":"Ishizawa K et al (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63:43\u201352","journal-title":"J Neuropathol Exp Neurol"},{"key":"13590_CR160","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/mds.21259","volume":"22","author":"AJ Langerveld","year":"2007","unstructured":"Langerveld AJ, Mihalko D, DeLong C, Walburn J, Ide CF (2007) Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. Mov Disord 22:766\u2013777","journal-title":"Mov Disord"},{"key":"13590_CR161","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-12-131","volume":"12","author":"P Novak","year":"2012","unstructured":"Novak P et al (2012) Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 12:131","journal-title":"BMC Neurol"},{"key":"13590_CR162","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mds.22732","volume":"25","author":"R Dodel","year":"2010","unstructured":"Dodel R et al (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25:97\u2013107","journal-title":"Mov Disord"},{"key":"13590_CR163","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12640-011-9294-3","volume":"21","author":"N Stefanova","year":"2012","unstructured":"Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK (2012) Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 21:393\u2013404","journal-title":"Neurotox Res"},{"key":"13590_CR164","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.2174\/138161210793176527","volume":"16","author":"M Naoi","year":"2010","unstructured":"Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharm Des 16:2799\u20132817","journal-title":"Curr Pharm Des"},{"key":"13590_CR165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1673-5374.375299","volume":"19","author":"M Alborghetti","year":"2024","unstructured":"Alborghetti M et al (2024) Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen Res 19:16\u201321","journal-title":"Neural Regen Res"},{"key":"13590_CR166","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","volume":"14","author":"W Poewe","year":"2015","unstructured":"Poewe W et al (2015) Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 14:145\u2013152","journal-title":"Lancet Neurol"},{"key":"13590_CR167","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.12.011","volume":"48","author":"EA Coon","year":"2018","unstructured":"Coon EA et al (2018) Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy? Parkinsonism Relat Disord 48:51\u201353","journal-title":"Parkinsonism Relat Disord"},{"key":"13590_CR168","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","volume":"234","author":"K Ubhi","year":"2012","unstructured":"Ubhi K et al (2012) Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of \u03b1-synucleinopathy. Exp Neurol 234:405\u2013416","journal-title":"Exp Neurol"},{"key":"13590_CR169","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/mds.28569","volume":"36","author":"O Rascol","year":"2021","unstructured":"Rascol O et al (2021) Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. Mov Disord 36:1704\u20131711","journal-title":"Mov Disord"},{"key":"13590_CR170","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113120","volume":"325","author":"G Vidal-Martinez","year":"2020","unstructured":"Vidal-Martinez G et al (2020) FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. Exp Neurol 325:113120","journal-title":"Exp Neurol"},{"key":"13590_CR171","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107701","volume":"158","author":"J Vargas-Medrano","year":"2019","unstructured":"Vargas-Medrano J et al (2019) FTY720-Mitoxy reduces toxicity associated with MSA-like \u03b1-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures. Neuropharmacology 158:107701","journal-title":"Neuropharmacology"},{"key":"13590_CR172","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jphs.2017.02.006","volume":"133","author":"I Segura-Ulate","year":"2017","unstructured":"Segura-Ulate I, Belcher TK, Vidal-Martinez G, Vargas-Medrano J, Perez RG (2017) FTY720-derivatives do not induce FTY720-like lymphopenia. J Pharmacol Sci 133:187\u2013189","journal-title":"J Pharmacol Sci"},{"key":"13590_CR173","first-page":"1004","volume":"29","author":"HI Choi","year":"2024","unstructured":"Choi HI et al (2024) Rat Pharmacokinetics and In Vitro Metabolite Identification of KM-819, a Parkinson\u2019s Disease Candidate. Using LC-MS\/MS and LC-HRMS. Molecules 29:1004","journal-title":"Using LC-MS\/MS and LC-HRMS. Molecules"},{"key":"13590_CR174","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3389\/fphar.2020.00953","volume":"11","author":"HS Park","year":"2020","unstructured":"Park HS et al (2020) Neurorestorative Effects of a Novel Fas-Associated Factor 1 Inhibitor in the MPTP Model: An [(18)F]FE-PE2I Positron Emission Tomography Analysis Study. Front Pharmacol 11:953","journal-title":"Front Pharmacol"},{"key":"13590_CR175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/DDDT.S198753","volume":"13","author":"W Shin","year":"2019","unstructured":"Shin W et al (2019) A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson\u2019s disease, in healthy volunteers. Drug Des Devel Ther 13:1011\u20131022","journal-title":"Drug Des Devel Ther"},{"key":"13590_CR176","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4062\/biomolther.2019.065","volume":"28","author":"R Hern\u00e1ndez","year":"2020","unstructured":"Hern\u00e1ndez R et al (2020) Differentiation of human mesenchymal stem cells towards neuronal lineage: clinical trials in nervous system disorders. Biomol Ther (Seoul) 28:34\u201344","journal-title":"Biomol Ther (Seoul)"},{"key":"13590_CR177","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.clpt.6100386","volume":"83","author":"PH Lee","year":"2008","unstructured":"Lee PH et al (2008) Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 83:723\u2013730","journal-title":"Clin Pharmacol Ther"},{"key":"13590_CR178","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","volume":"72","author":"PH Lee","year":"2012","unstructured":"Lee PH et al (2012) A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 72:32\u201340","journal-title":"Ann Neurol"},{"key":"13590_CR179","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/WNL.0000000000007720","volume":"93","author":"W Singer","year":"2019","unstructured":"Singer W et al (2019) Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology 93:e77\u2013e87","journal-title":"Neurology"},{"key":"13590_CR180","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101920","volume":"59","author":"J Mitsui","year":"2023","unstructured":"Mitsui J et al (2023) High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial. EClinicalMedicine 59:101920","journal-title":"EClinicalMedicine"},{"key":"13590_CR181","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.amjmed.2017.10.021","volume":"131","author":"CM Rembold","year":"2018","unstructured":"Rembold CM (2018) Coenzyme Q10 supplementation in orthostatic hypotension and multiple-system atrophy: a report on 7 cases. Am J Med 131:444\u2013446","journal-title":"Am J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13590-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:57:44Z","timestamp":1773665864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13590-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":181,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13590"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13590-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest or financial disclosures related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"49"}}